[en] Three new therapies for spinal muscular atrophy (SMA) have been approved by the United States Food and Drug Administration and the European Medicines Agency since 2016. Although these new therapies improve the quality of life of patients who are symptomatic at first treatment, administration before the onset of symptoms is significantly more effective. As a consequence, newborn screening programs have been initiated in several countries. In 2018, we launched a 3-year pilot program to screen newborns for SMA in the Belgian region of Liège. This program was rapidly expanding to all of Southern Belgium, a region of approximately 55,000 births annually. During the pilot program, 136,339 neonates were tested for deletion of exon 7 of SMN1, the most common cause of SMA. Nine SMA cases with homozygous deletion were identified through this screen. Another patient was identified after presenting with symptoms and was shown to be heterozygous for the SMN1 exon 7 deletion and a point mutation on the opposite allele. These ten patients were treated. The pilot program has now successfully transitioned into the official neonatal screening program in Southern Belgium. The lessons learned during implementation of this pilot program are reported.
Disciplines :
Genetics & genetic processes
Author, co-author :
BOEMER, François ; Centre Hospitalier Universitaire de Liège - CHU > Unilab > Laboratoire Biochimie Génétique
Lefebvre, S. et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80, 155–165 (1995). DOI: 10.1016/0092-8674(95)90460-3
Kolb, S. J. et al. Natural history of infantile-onset spinal muscular atrophy. Ann. Neurol. 82, 883–891 (2017). DOI: 10.1002/ana.25101
Ramdas, S. & Servais, L. New treatments in spinal muscular atrophy: An overview of currently available data. Expert Opin. Pharmacother. 21, 307–315 (2020). DOI: 10.1080/14656566.2019.1704732
Finkel, R. S. et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N. Engl. J. Med. 377, 1723–1732 (2017). DOI: 10.1056/NEJMoa1702752
Mendell, J. R. et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N. Engl. J. Med. 377, 1713–1722 (2017). DOI: 10.1056/NEJMoa1706198
Baranello, G. et al. Risdiplam in type 1 spinal muscular atrophy. N. Engl. J. Med. 384, 915–923 (2021). DOI: 10.1056/NEJMoa2009965
Servais, L., Baranello, G., Scoto, M., Daron, A. & Oskoui, M. Therapeutic interventions for spinal muscular atrophy: Preclinical and early clinical development opportunities. Expert Opin. Investig. Drugs 10.1080/13543784.2021.1904889 (2021). DOI: 10.1080/13543784.2021.1904889
Govoni, A., Gagliardi, D., Comi, G. P. & Corti, S. Time is motor neuron: Therapeutic window and its correlation with pathogenetic mechanisms in spinal muscular atrophy. Mol. Neurobiol. 55, 6307–6318 (2018). DOI: 10.1007/s12035-017-0831-9
De Vivo, D. C. et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul. Disord. 29, 842–856 (2019). DOI: 10.1016/j.nmd.2019.09.007
Pyatt, R. E. & Prior, T. W. A feasibility study for the newborn screening of spinal muscular atrophy. Genet. Med. 8, 428–437 (2006). DOI: 10.1097/01.gim.0000227970.60450.b2
Prior, T. W. et al. Newborn and carrier screening for spinal muscular atrophy. Am. J. Med. Genet. Part A 152, 1608–1616 (2010). DOI: 10.1002/ajmg.a.33474
Chien, Y.-H. et al. Presymptomatic diagnosis of spinal muscular atrophy through newborn screening. J. Pediatr. 190, 124-129.e1 (2017). DOI: 10.1016/j.jpeds.2017.06.042
Kraszewski, J. N. et al. Pilot study of population-based newborn screening for spinal muscular atrophy in New York state. Genet. Med. 20, 608–613 (2018). DOI: 10.1038/gim.2017.152
Dangouloff, T. et al. 244th ENMC international workshop: Newborn screening in spinal muscular atrophy May 10–12, 2019, Hoofdorp, the Netherlands. Neuromuscul. Disord. 30, 93–103 (2020). DOI: 10.1016/j.nmd.2019.11.002
McMillan, H. J. et al. Newborn screening for spinal muscular atrophy: Ontario testing and follow-up recommendations. Can. J. Neurol. Sci. (2020). https://doi.org/10.1017/cjn.2020.229
Shinohara, M. et al. A novel system for spinal muscular atrophy screening in newborns: Japanese pilot study. Int. J. Neonatal Screen. 5, 41 (2019). DOI: 10.3390/ijns5040041
Vill, K. et al. One year of newborn screening for SMA—results of a German pilot project. J. Neuromuscul. Dis. 6, 503–515 (2019). DOI: 10.3233/JND-190428
Kariyawasam, D. S. T. T., Russell, J. S., Wiley, V., Alexander, I. E. & Farrar, M. A. The implementation of newborn screening for spinal muscular atrophy: The Australian experience. Genet. Med. 22, 557–565 (2020). DOI: 10.1038/s41436-019-0673-0
Kemper, A. R. et al. Evidence-based review of newborn screening for spinal muscular atrophy (SMA): Final report (v5.2). USA Matern. Child Heal. Bur. United States Secr. Heal. Hum. Serv. Advis. Comm. Heritable Disord. Newborns Child. 5, 108 (2018).
Boemer, F. et al. Newborn screening for SMA in Southern Belgium. Neuromuscul. Disord. 29, 343–349 (2019). DOI: 10.1016/j.nmd.2019.02.003
Boemer, F. et al. (S)un (M)ay (A)rise on SMA: The hope of a region without spinal muscular atrophy. Rev. Med. Liège 74, 461 (2019).
Czibere, L. et al. High-throughput genetic newborn screening for spinal muscular atrophy by rapid nucleic acid extraction from dried blood spots and 384-well qPCR. Eur. J. Hum. Genet. 28, 23–30 (2020). DOI: 10.1038/s41431-019-0476-4
Kay, D. M. et al. Implementation of population-based newborn screening reveals low incidence of spinal muscular atrophy. Genet. Med. 22, 1296–1302 (2020). DOI: 10.1038/s41436-020-0824-3
Dangouloff, T., Boemer, F., Caberg, J.-H. & Servais, L. Correspondence on: “Discrepancy in Spinal Muscular Atrophy Incidence findings in newborn screening programs: The influence of carrier screening?” by Kay et al. Genet. Med. (2020). 10.1038/s41436-020-0887-1
Wirth, B. An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Hum. Mutat. 15, 228–237 (2000). DOI: 10.1002/(SICI)1098-1004(200003)15:3<228::AID-HUMU3>3.0.CO;2-9
Dangouloff, T. & Servais, L. Clinical evidence supporting early treatment of patients with spinal muscular atrophy: Current perspectives. Ther. Clin. Risk Manag. 15, 1153–1161 (2019). DOI: 10.2147/TCRM.S172291
Dangouloff, T., Botty, C., Beaudart, C., Servais, L. & Hiligsmann, M. Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments. Orphanet J. Rare Dis. 16, 47 (2021). DOI: 10.1186/s13023-021-01695-7
Darras, B. T. et al. Neurofilament as a potential biomarker for spinal muscular atrophy. Ann. Clin. Transl. Neurol. 6, 932–944 (2019). DOI: 10.1002/acn3.779
Dangouloff, T., Vrščaj, E., Servais, L., Osredkar, D. & Group, S. N. W. S. Newborn screening programs for spinal muscular atrophy worldwide: Where we stand and where to go. Neuromusc. Disord. 31(6), 574–582 (2021). DOI: 10.1016/j.nmd.2021.03.007
Blasco-Pérez, L. et al. Beyond copy number: A new, rapid, and versatile method for sequencing the entire SMN2 gene in SMA patients. Hum. Mutat. 42, 787–795 (2021). DOI: 10.1002/humu.24200
